Gore Excluder Conformable内假体治疗短且非成角肾下锚定区腹主动脉瘤的5年关键试验结果
EXCC美国关键试验短颈亚组前瞻性纳入80例肾下颈长≥10 mm且≤60°的AAA患者,5年随访显示无动脉瘤相关死亡、转开放、内漏、移位或闭塞,AAA扩张≥5 mm者10.3%,再干预11.3%,破裂1.3%;颈长≥10至<15 mm与≥15 mm亚组间AAA扩张(9.5% vs 10.5%)和再干预(8.7% vs 12.3%)无显著差异(P=1.0)。
要点
- EXCC在颈长≥10 mm且≤60°的AAA中5年无动脉瘤相关死亡、转开放、I/III型内漏或器械闭塞/移位。
- 5年AAA扩张≥5 mm发生率10.3%,再干预11.3%(主要为II型内漏栓塞),破裂1.3%。
- 颈长≥10至<15 mm与≥15 mm亚组的AAA扩张和再干预无显著差异(P=1.0)。
核心结论
- EXCC美国关键试验5年结果显示患者安全性和器械有效性终点优异,无动脉瘤相关死亡、转开放、显著内漏或器械闭塞/移位。
- 再干预和AAA囊扩张不常见,且在短或标准肾下锚定区长度之间无差异。
- EXCC装置对颈长≥10 mm且≤60°成角的AAA患者5年内安全有效。
研究设计与样本
- EXCC研究器械豁免前瞻性关键试验的短颈亚研究,覆盖31个中心。
- 纳入肾下颈长≥10 mm且成角≤60°的患者,共植入80例,其中颈长<15 mm者23例(29%),≥15 mm者57例(71%)。
- 患者平均年龄73.5±8.1岁,93.8%为白人,平均体质指数29.5±5.1 kg/m2。
- 5年时15例死亡,12例失访,剩余53例中47例有5年随访数据。
- 平均最大AAA直径57.7 mm(范围42.5-82.7 mm),平均肾下主动脉角度35.7°(范围3°-59°)。
主要发现
- 5年内无动脉瘤相关死亡、转开放、梗阻、闭塞、侵蚀、移位或I型/III型内漏报告。
- AAA扩张≥5 mm发生于8例(10.3%),9例(11.3%)接受再干预,主要为II型内漏栓塞。
- 1例(1.3%)发生AAA破裂。
- 颈长≥10至<15 mm vs ≥15 mm亚组的AAA扩张率9.5% vs 10.5%,再干预率8.7% vs 12.3%,差异无显著(P=1.0)。
关键数值与推荐
- EXCC获美国批准用于治疗AAA及高度成角(≤90°)和短(≥10 mm)肾下主动脉近端锚定区(颈)。
- 短颈亚研究纳入标准:肾下颈长≥10 mm且成角≤60°。
- 5年终点由核心实验室评估并由独立审查委员会裁定。
临床怎么用
- 对于肾下颈长≥10 mm且成角≤60°的AAA患者,EXCC装置5年随访显示安全有效。
- 短颈(≥10至<15 mm)与标准颈(≥15 mm)患者的再干预和AAA扩张风险无显著差异。
- 再干预主要针对II型内漏,需在随访中关注。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The GORE EXCLUDER Conformable Abdominal Aortic Aneurysm Endoprosthesis with Active Control System (EXCC) is approved in the United States (U.S.) for treatment of AAAs and highly angulated (≤90°) and short (≥10 mm) infrarenal aortic proximal seal zones (necks). Reported here are the 5-year outcomes of the EXCC U.S. pivotal clinical trial in the short, non-angulated cohort (SNA). METHODS: The EXCC investigational device exemption prospective pivotal trial short neck sub-study across 31 sites included patients with infrarenal necks measuring ≥10 mm length and ≤60° angulation. Five-year outcomes assessed by Core lab and adjudicated by independent review committee included patient safety (mortality, reintervention, rupture, conversion to open repair), device effectiveness (freedom from endoleak, migration, fracture, erosion, occlusion), and freedom from aneurysm sac expansion in the SNA cohort and subpopulations of patients with neck length of ≥10 mm to <15 mm and ≥15 mm. RESULTS: The EXCC device was implanted in 80 SNA patients, of which 23 (29%) had <15 mm neck length and 57 (71%) had ≥15 mm. Patients were a mean age of 73.5 ± 8.1 years, 93.8% White, and had a mean body mass index of 29.5 ± 5.1 kg/m2. At 5 years, 15 patients died, 12 were lost to follow-up, and for 47 of the 53 remaining patients, 5-year follow-up data was available. The mean maximum abdominal aortic aneurysm (AAA) diameter was 57.7 mm (range, 42.5-82.7 mm), and the mean infrarenal aortic angle was 35.7° (range, 3°-59°). Through 5 years, no aneurysm-related mortality, conversion to open repair, obstruction, occlusion, erosion, migration, or type I or type III endoleaks were reported. AAA expansion ≥5 mm occurred in eight patients (10.3%). Nine patients (11.3%) underwent reintervention, predominantly embolization for type II endoleak. One patient (1.3%) experienced an AAA rupture. In patients with a ≥10 mm to <15 mm seal zone vs a ≥15 mm seal zone, differences in AAA expansion (9.5% vs 10.5%) or reinterventions (8.7% vs 12.3%) were not significant (P = 1.0). CONCLUSIONS: The 5-year outcomes of the EXCC U.S. pivotal trial demonstrate excellent patient safety and device effectiveness endpoints. There is complete absence of aneurysm-related mortality, conversion to open repair, significant endoleak, or device occlusion/migration. Reinterventions and AAA sac expansion are infrequent and do not differ between short or standard infrarenal seal zone lengths. The EXCC device is safe and effective through 5 years for AAA necks measuring ≥10 mm length and ≤60° angulation.
引用
- Suckow BD, Oderich GS, Almadani MW, et al. Five-year pivotal trial outcomes of the Gore Excluder conformable endoprosthesis implanted in abdominal aortic aneurysms with short non-angulated infrarenal seal zones. J Vasc Surg. 2025. PMID: 40464725. doi:10.1016/j.jvs.2025.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。